# Cartesian Therapeutics

Source: https://onco.cc/companies/cartesian-therapeutics/  
OnCo record `cartesian-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cartesian makes CAR-T cells from messenger RNA rather than permanent gene insertion, so the cells work for days and then fade; it began in myeloma and now leads phase 3 trials in autoimmune disease.

## Summary

Cartesian Therapeutics, based in Frederick, Maryland, engineers T cells with mRNA-encoded chimeric antigen receptors, giving a transient product that can be dosed repeatedly without lymphodepletion. Its BCMA-directed Descartes-08 was first tested in multiple myeloma before the company focused on myasthenia gravis and other autoimmune diseases, where it leads phase 3 trials. Its myeloma trials remain on ClinicalTrials.gov under Cartesian as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Cartesian Therapeutics, Inc.; Cartesian
- Tags: ctgov-sponsor
- HQ: Frederick, MD
- Type: cell-therapy
- Website: https://www.cartesiantherapeutics.com

## Sources

- Official website: https://www.cartesiantherapeutics.com
- ClinicalTrials.gov: trials led by Cartesian Therapeutics, Inc.: https://clinicaltrials.gov/search?lead=Cartesian%20Therapeutics%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q140045331

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/cartesian-therapeutics.json